Navigation Links
Mitochondrial genome mutates when reprogrammed
Date:7/28/2011

This release is available in German.

Induced pluripotent stem cells (iPS cells) are truly talented multi-taskers. They can reproduce almost all cell types and thus offer great hope in the fight against diseases like Alzheimer's and Parkinson's. However, it would appear that their use is not entirely without risk: during the reprogramming of body cells into iPS cells, disease-causing mutations can creep into the genetic material. The genome of the mitochondria the cell's protein factories is particularly vulnerable to such changes. This phenomenon has been discovered by researchers at the Max Planck Institute for Molecular Genetics in Berlin. The scientists encountered mutations in the mitochondrial genome of iPS cells. Because such genetic mutations can cause diseases, the cells should be tested for such mutations before being used for clinical applications.

A lot of hope is riding on induced pluripotent stem cells (iPS cells). Because they can be generated individually for every single person, they are expected to enable the development of tailor-made therapies that do not run the risk of triggering rejection reactions. iPS cells also offer a promising solution for drug screening, as researchers can generate different cell types such as liver cells from them, on which they can then test the effect of substances. iPS cells can be generated from adult body cells using the technique of "cellular reprogramming". The method raises no ethical concerns as it does not involve the destruction of embryos.

However, these promising cells are also associated with certain risks. Disease-causing mutations can also arise during the reprogramming of the body cells. The genetic material in the mitochondria is particularly vulnerable to changes in the genetic code. The question as to whether such mutations arise as a result of the reprogramming process had not previously been investigated.

A cooperative research study involving two research groups from the Max Planck Institute for Molecular Genetics in Berlin has now carried out a search for mutations in the mitochondrial genome of iPS cells. James Adjaye's research group recently discovered that the mitochondria rejuvenate in the course of reprogramming. Working in cooperation with Bernd Timmermann's Next Generation Sequencing research group, Adjaye's team has succeeded in showing that genetic mutations exist in the mitochondrial genome of all reprogrammed cells that were not present in the original cells. The amount of mutations varies significantly between the individual iPS cells examined. In all cases, the changes did not involve large-scale rearrangements but rather modifications of single letters in the genetic code.

"The mitochondrial genome undergoes random reorganisation during reprogramming," explains James Adjaye. "Cell lines can arise in the process that carries disease-causing mutations. Genetic mutations in the mitochondrial genome may be responsible, for example, for various metabolic disorders, nervous diseases, tumours and post-transplant rejection reactions. Therefore, it is essential that cell lines intended for clinical use be tested for such mutations," he adds.

One of the reasons why the mitochondrial genome is so vulnerable to mutations is that mitochondria do not have the ingenious molecular repair mechanisms found in the cell nucleus at their disposal. In addition, free radicals particularly reactive molecules that can trigger mutations arise in the cellular protein factories during cellular respiration.

For their study, the scientists generated iPS cells from human skin cells (fibroblasts). Based on a standard procedure, they used viruses as a vehicle for the infiltration of certain regulator genes into the skin cells. These genes, which are usually only active in the embryo, transpose the cell back to a juvenile state. As a result it gains the potential to differentiate into almost all of the cell types found in the human body, in other words, it becomes pluripotent.


'/>"/>

Contact: Dr. James Adjaye
adjaye@molgen.mpg.de
49-308-413-1203
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. PGD can permit the birth of healthy children to women carrying mitochondrial DNA disease
2. Nitrate improves mitochondrial function
3. Cell death pathway linked to mitochondrial fusion
4. Extracting cellular engines may aid in understanding mitochondrial diseases
5. Children with autism more likely to have mitochondrial defects impacting cellular energy production
6. How mitochondrial gene defects impair respiration, other major life functions
7. BGI develops new strategy to uncover structural variations of human genomes
8. BGI and National Wolfberry Engineering Research Center launch Chinese wolfberry genome project
9. The first studies utilizing the Collaborative Cross mice are published in Genome Research
10. BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research
11. Simple little spud helps scientists crack potatos mighty genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mitochondrial genome mutates when reprogrammed
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/4/2016)... OXFORD, England , February 4, 2016 ... Advanced Bioscience Laboratories (ABL), Inc. --> Strasbourg, ... (ABL), Inc. --> PharmaVentures is pleased to announce ... sale of its biopharmaceutical manufacturing unit in Strasbourg, ... (ABL), Inc. --> --> ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
Breaking Biology Technology: